Mary C Kuhns

Summary

Affiliation: Abbott Laboratories
Country: USA

Publications

  1. ncbi Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy
    Mary C Kuhns
    Abbott Laboratories, Abbott Park, Illinois, USA
    Transfusion 44:1332-9. 2004
  2. ncbi New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods
    Mary C Kuhns
    Abbott Diagnostics, Abbott Park, Illinois 60064, USA
    Mol Diagn Ther 10:77-91. 2006
  3. ncbi HIV variants and hepatitis B surface antigen mutants: diagnostic challenges for immunoassays
    Gerald Schochetman
    Infections Disease Diagnostics, R and D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    J Med Virol 78:S3-6. 2006
  4. ncbi Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening
    Steven H Kleinman
    Westat, Rockville, Maryland, USA
    Transfusion 43:696-704. 2003
  5. ncbi Surveillance of the genetic variation in incident HIV, HCV, and HBV infections in blood and plasma donors: implications for blood safety, diagnostics, treatment, and molecular epidemiology
    Eric Delwart
    Blood Systems Research Institute, and Department of Laboratory Medicine, University of California, San Francisco, California, USA
    J Med Virol 78:S30-5. 2006

Collaborators

Detail Information

Publications5

  1. ncbi Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy
    Mary C Kuhns
    Abbott Laboratories, Abbott Park, Illinois, USA
    Transfusion 44:1332-9. 2004
    ..Studies showing a significant correlation between hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels have focused on the HBV seroconversion window period...
  2. ncbi New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods
    Mary C Kuhns
    Abbott Diagnostics, Abbott Park, Illinois 60064, USA
    Mol Diagn Ther 10:77-91. 2006
    ..Each country will need to develop its blood screening strategy based on HBV endemicity, yields of infectious units detected by different serologic/NAT screening methods, and cost effectiveness of test methods in ensuring blood safety...
  3. ncbi HIV variants and hepatitis B surface antigen mutants: diagnostic challenges for immunoassays
    Gerald Schochetman
    Infections Disease Diagnostics, R and D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    J Med Virol 78:S3-6. 2006
  4. ncbi Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening
    Steven H Kleinman
    Westat, Rockville, Maryland, USA
    Transfusion 43:696-704. 2003
    ..An estimate of the rate of HBV DNA-positive, anti-HBc-positive units is important for evaluating the need for anti-HBc donor screening, especially in the context of HBV NAT...
  5. ncbi Surveillance of the genetic variation in incident HIV, HCV, and HBV infections in blood and plasma donors: implications for blood safety, diagnostics, treatment, and molecular epidemiology
    Eric Delwart
    Blood Systems Research Institute, and Department of Laboratory Medicine, University of California, San Francisco, California, USA
    J Med Virol 78:S30-5. 2006
    ..A systematic program is proposed for the genetic characterization of viral genomes in donors with incident HIV, HCV, or HBV infections...